Ignite Creation Date:
2024-05-06 @ 6:11 PM
Last Modification Date:
2024-10-26 @ 2:43 PM
Study NCT ID:
NCT05577442
Status:
UNKNOWN
Last Update Posted:
2022-10-19
First Post:
2022-10-09
Brief Title:
Trastuzumab Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR HER2 Advanced Breast Cancer
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Organization Data
Organization:
Peking University Cancer Hospital Institute
Class:
OTHER
Study ID:
OBU-BC-Ⅱ-077
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Peking University Cancer Hospital Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Li Huiping
Responsible Party Title:
Head of the department of breast oncology
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Peking University Cancer Hospital Institute
Old Name:
None
Old Organization:
None